Cyclooxygenase-2 expression in Barrett's esophagus

H. M. Kandil, G. Tanner, W. Smalley, S. Halter, A. Radhika, R. N. Dubois

Research output: Contribution to journalArticle

86 Scopus citations

Abstract

Barrett's epithelium is a recognized premalignant condition for esophageal adenocarcinoma. Nonsteroidal antiinflammatory drugs (NSAIDs) decrease the relative risk of colon cancer in humans and the esophageal tumor load in carcinogen-treated mice. Previous studies provided conflicting results for COX-2 activity in Barrett's mucosa. Pinch mucosal biopsies were collected from Barrett's and adjacent normal esophageal mucosa from 17 patients with Barrett's esophagus. Low-grade dysplasia was found in seven patients. COX-2 protein was undetectable in normal esophageal mucosa. COX-1 protein expression did not vary between normal and Barrett's epithelium. Increased COX-2 protein was detected in Barrett's epithelium in seven patients (41%) but did not differ with or without dysplasia (43% vs 40%). In conclusion, COX-2 protein is increased in 41% of patients with Barrett's epithelium compared to normal esophageal mucosa but did not differ with or without dysplasia. COX-2 induction may be an early event in the development of Barrett's esophagus.

Original languageEnglish (US)
Pages (from-to)785-789
Number of pages5
JournalDigestive Diseases and Sciences
Volume46
Issue number4
DOIs
StatePublished - 2001
Externally publishedYes

Keywords

  • Barrett's esophagus
  • COX-2
  • Dysplasia

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Cyclooxygenase-2 expression in Barrett's esophagus'. Together they form a unique fingerprint.

  • Cite this

    Kandil, H. M., Tanner, G., Smalley, W., Halter, S., Radhika, A., & Dubois, R. N. (2001). Cyclooxygenase-2 expression in Barrett's esophagus. Digestive Diseases and Sciences, 46(4), 785-789. https://doi.org/10.1023/A:1010700400960